The global prostate cancer therapeutics market size was estimated at USD 17.0 billion in 2024 and is projected to reach USD 31.99 billion by 2030, expanding at a CAGR of 10.9% from 2025 to 2030. This steady growth is primarily driven by the increasing incidence of prostate cancer worldwide, particularly among aging male populations, along with continuous improvements in screening and diagnostic technologies. Early detection through advanced diagnostic tools has enabled timely treatment initiation, thereby increasing the demand for effective therapeutic solutions. In addition, government initiatives supporting cancer research, reimbursement programs, and regulatory approvals for novel treatments are playing a crucial role in accelerating market growth. The integration of advanced technologies such as bioinformatics and computational biology is further transforming therapy development by enabling precision medicine approaches. Market players are increasingly leveraging techniques such as proteome profiling and genome sequencing to design more targeted and effective treatments. For example, in 2022, a phase III clinical trial for Olaparib involved over 4,000 men and utilized tumor genomic testing to identify patients most likely to benefit from the therapy.

The global pandemic had a substantial impact on the prostate cancer therapeutics market, leading to disruptions in routine healthcare services and altering clinical practices. Restrictions on hospital visits and reduced face-to-face doctor-patient interactions delayed diagnoses, treatment initiation, and follow-up care for many patients. Limited access to healthcare facilities and diagnostic services further affected treatment continuity, while clinical decisions were influenced by the need to minimize patient exposure to healthcare settings. Additionally, the pandemic intensified existing social and economic challenges, exacerbating disparities in healthcare access across different populations. These factors negatively influenced prostate cancer outcomes, and patients with prostate cancer were observed to have a higher risk of severe complications and mortality from COVID-19 compared to individuals without cancer.

Leading players operating in the prostate cancer therapeutics market are increasingly focusing on the development of novel and advanced treatment options. Many pharmaceutical companies have a strong pipeline of products that are expected to be launched during the forecast period, supporting sustained market expansion. Strategic initiatives such as clinical trials, product innovation, and combination therapies are central to these efforts. For instance, in March 2022, Merck announced the KEYLYNK-010 clinical trial, which aimed to evaluate the efficacy of Keytruda in combination with Lynparza in patients with metastatic castration-resistant prostate cancer. Such combination approaches are intended to improve therapeutic outcomes by targeting multiple disease pathways simultaneously.

Key Market Trends & Insights:

• North America dominated the global prostate cancer therapeutics market in 2024, accounting for a revenue share of 40.8%. This dominance is largely attributed to the high prevalence of prostate cancer in the region, well-established healthcare infrastructure, and strong demand for advanced therapeutic products. The U.S. prostate cancer therapeutics market held the largest share within North America in 2024, supported by widespread adoption of innovative treatments, favorable reimbursement frameworks, and strong presence of leading pharmaceutical companies.
• The Asia Pacific prostate cancer therapeutics market is expected to grow at the fastest CAGR of 9.9% over the forecast period. Factors such as the availability of more affordable treatment options, increasing adoption of personalized medicine, rapid technological advancements, and a rising number of prostate cancer cases are driving market growth in the region.
• By drug class, hormonal therapy dominated the market in 2024, accounting for a substantial revenue share of 88.6%. Hormonal therapies remain a cornerstone in prostate cancer treatment due to their effectiveness in controlling disease progression. Meanwhile, the immunotherapy drug class is expected to witness notable growth, driven by advancements in immune checkpoint inhibitors and the increasing adoption of personalized and precision-based treatment strategies.
• By distribution channel, the hospital pharmacies segment dominated the market and accounted for the largest revenue share of 48.2% in 2024. Hospital pharmacies play a critical role in dispensing specialized cancer medications and supporting complex treatment regimens. In contrast, online pharmacies are expected to register a lucrative growth rate of 8.8% over the forecast period. This growth is attributed to improved internet accessibility, rising consumer awareness regarding over-the-counter medicines, and the convenience offered by online platforms, which have gained rapid popularity in recent years.

Order a free sample PDF of the Prostate Cancer Therapeutics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 17.0 billion
• 2030 Projected Market Size: USD 31.99 billion
• CAGR (2025-2030): 10.9%
• North America: Largest market in 2024

Key Companies & Market Share Insights:

Several key companies are actively operating in the prostate cancer therapeutics market, including Johnson & Johnson Services, Inc., Astellas Pharma Inc., and Eli Lilly and Company. These players are strengthening their market presence through strategies such as new product launches, strategic collaborations, mergers, and continuous investment in research and development.

• Johnson & Johnson Services, Inc. is a prominent participant in the prostate cancer therapeutics market, offering advanced treatment options aimed at improving patient outcomes across various stages of the disease. The company’s product portfolio includes innovative hormone therapies and targeted treatments designed to address different disease severities. With a strong focus on research and development, Johnson & Johnson is exploring next-generation androgen receptor inhibitors and combination therapies to enhance treatment efficacy. Its ongoing commitment to oncology innovation supports the development of new and effective therapeutic options for prostate cancer patients worldwide.
• Astellas Pharma Inc. is another significant player, providing therapies that target multiple stages of prostate cancer. The company specializes in the development of androgen receptor inhibitors and other targeted treatments aimed at improving clinical outcomes. Through extensive research efforts and clinical trials, Astellas Pharma evaluates new therapeutic combinations and personalized treatment approaches. Its continued focus on oncology research contributes to the expanding availability of advanced treatment options within the global prostate cancer therapeutics market.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The prostate cancer therapeutics market is witnessing strong growth driven by the rising global incidence of prostate cancer, advancements in diagnostic technologies, and increasing adoption of precision medicine approaches. Continuous innovation in bioinformatics, genomic profiling, and targeted therapies is enabling the development of more effective and personalized treatment options. Despite temporary disruptions caused by the COVID-19 pandemic, the market has regained momentum as healthcare systems normalize and delayed treatments resume. Ongoing clinical trials and robust product pipelines from leading pharmaceutical companies are expected to support sustained market expansion. However, the high cost of targeted therapies remains a key challenge, potentially limiting accessibility in certain regions. Overall, supportive government initiatives, technological advancements, and increasing awareness are expected to positively shape the future outlook of the prostate cancer therapeutics market.